Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on CLARIANT AG-REG. We currently have 7 research reports from 1 professional analysts.
Frequency of research reports
Research reports on
28 Oct 16
Clariant’s trading statement reported sales a bit weaker (-1% at CHF1,400m; +2% in LC) and an unchanged EBITDA before one-offs at CHF208m (-3% in LC). For 2016, management expects to generate growth in local currencies as well as increases in operating cash flow and EBITDA margin before one-offs, which is confirmation of the guidance given earlier this year.
Strong operating CF improvement, but net income suffers
28 Jul 16
Clariant reported slightly higher sales (+1% to CHF2,899m) in H1, but volumes were even higher at +3%. The gross profit margin was up at 31.7% (30.8%), but EBITDA weakened (-1% to €395m). Net income attributable to shareholders declined 10% to CHF123m. Operating CF jumped from CHF65m to CHF208m, propelled by lower restructuring payments and tax payments as well as a reduced NWC outflow (CHF-181m after CHF-232m). The latter benefited from the swing into positive figures of other current assets and liabilities as well as provisions. Investing CF (CHF-168m after CHF-279m) was predominately driven by the swing in current financial assets (CHF39m after CHF-222m). Financing CF came down from CHF167m to CHF88m mainly due to the lower net gross debt proceeds (CHF273m after CHF342m). For 2016, management expects to generate growth in local currencies as well as progress in operating cash flow and the EBITDA margin before one-offs, which is confirmation of the guidance given earlier this year.
25 Jul 16
The papers say, Clariant is preparing for a large acquisition, playing an active part in the current consolidation game. Management, especially Dr Kottmann, is in discussions with banks and investors in order to secure the financing of the potential deal. Insiders said, the company is looking for some USD100m, which might be ‘collected’ by the issuance of a corporate bond and could be available in August. The USA is currently under-represented and other Chemicals companies have already ‘found’ attractive, but not cheap, targets there.
28 Apr 16
Clariant has decided to provide the full set of financial figures only twice a year. Group sales were up +1% to CHF1,478m as volumes rose +3% and EBITDA pre one-offs went up +11% to CHF229m. For 2016, management expects to generate growth in local currencies as well as progress in operating cash flow and the EBITDA margin before one-offs, which is confirmation of the guidance given earlier this year.
Q4 gives operating CF a nice push
17 Feb 16
Q4 sales continued to suffer from FX headwinds (-8%) bringing it down by 4% to CHF1,526m. Partly benefiting from the lower raw material prices and a mix effect, the gross profit margin improved from 28.8% to 30.0%, but EBITDA clearly dropped 47% to CHF177m. As a reminder, there were some disposal gains (CHF164m) booked in Q4 14. Net profit attributable came in at CHF27m after CHF80m. Q4 operating CF was a bit weaker (CHF306m after CHF321m), but NWC (CHF205m after CHF221m) remained at its high level. Despite higher capex and significantly lower income from disposal gains, investing CF came in at CHF33m (CHF14m) helped by an inflow from near cash assets. Financing CF moved from CHF-210m to CHF-283m, fuelled by higher net gross debt repayments (CHF-243m after CHF-205m). Management proposes an unchanged dividend of CHF0.40 per share at the AGM on 21 April 2016. For 2016, management expects to generate growth in local currencies as well as increasing operating cash flow and the EBITDA margin before one-offs.
Operating CF is on the right track
29 Oct 15
Sales declined 6% (organic: +2%) to CHF1,410m but the gross profit margin improved 80bp to 31.6%. EBITDA remained unchanged at CHF191m and net income attributable to shareholders increased +18% to CHF65m. Operating CF continued to stay in the black (CHF131m after CHF126m), which is normal for Q3, but NWC outflow was slightly up (CHF-41m after CHF-31m). Investing CF (CHF-89m after CHF-144m) saw a CHF85m swing to a CHF19m inflow from current financial assets, which was partly offset by higher capex and acquisition costs. Financing CF swung from CHF-66m to CHF32m primarily due to net gross debt proceeds of CHF48m (CHF-44m). Management confirmed FY guidance, still expecting sales to grow by a low to mid single-digit percentage on local currencies and a higher EBITDA margin before one-offs compared to 2014 as well as an increased CF generation.
N+1 Singer - Best Ideas 2017 - Top picks
04 Jan 17
Today we publish our Best Ideas for 2017 - 12 stocks that we believe have excellent prospects in the current year together with a detailed discussion of what we see as the key sector and market themes for 2017. Our top picks are Cineworld, Elementis, Herald Investment Trust, Hill & Smith, IQE, MySale, Redde, ReNeuron, RhythmOne, SDL, Servelec and Severfield.
19 Dec 16
600 GROUP | ACCSYS TECHNOLOGIES | AGGREGATED MICRO POWER HLDGS PLC | ALUMASC GROUP | ANGLO-EASTERN PLANTATIONS | AVINGTRANS PLC | CAPITAL DRILLING LTD | CARCLO | FENNER PLC | FLOWTECH FLUIDPOWER PLC | GLOBAL INVACOM GROUP LTD | GOOCH & HOUSEGO PLC | HARDIDE PLC | HAYWARD TYLER GROUP PLC | IOFINA PLC | M.P.EVANS GROUP | R.E.A. HLDGS PLC | REDT ENERGY PLC | RENOLD | ROBINSON | SOMERO ENTERPRISE INC | SURFACE TRANSFORMS PLC | TRANSENSE TECHNOLOGIES PLC | TRIFAST | ZAMBEEF PRODUCTS
A Quarterly look at UK Healthcare
02 Nov 16
Today we publish PG:GP (Panmure Gordon: Growth Prospects), our first quarterly take on the healthcare sector. We see current macro volatility providing a strong backdrop for the more naturally defensive healthcare stocks which are underpinned by solid fundamental drivers. The run-up to the US Presidential election has repeatedly reminded us that pharmaceutical pricing is one of Hilary Clinton’s main targets, and whatever the result, we see a see greater emphasis on outcomes-based pricing and reimbursement as a major influence for the future. In the UK, concerns voiced by the pharma majors over use of new drugs in the UK post Brexit may encourage adoption of some of the recommendations published last week in the UK Government’s final report on the Accelerated Access Review.
Small Cap Breakfast
21 Dec 16
Ultimate Products—The Telegraph reports Jim McCarthy, former chief of Poundland has been appointed Chairman of Ultimate Products ahead of a £100m listing in H1 2017. Ultimate Products owns the Beldray cleaning brand and the licence to sell Russell Hobbs and Salter electrical products in the UK.
N+1 Singer - Strategy - Best Ideas 2017
04 Jan 17
Today we publish our Best Ideas for 2017. We have chosen 12 stocks that we believe have excellent prospects in the current year, together with an in depth discussion of what we see as the key sector and market themes for 2017. Our top picks are Cineworld, Elementis, Herald Investment Trust, Hill & Smith, IQE, MySale, Redde, ReNeuron, RhythmOne, SDL, Servelec, Severfield. Please see the separate note for further details.
Small Cap Breakfast
12 Dec 16
ECSC—Schedule 1 from provider of cyber security services. Raising £5m. Vendor sale £0.9m. Target date 14 Dec. Expected market cap £15m, with issue price of 167p. RM Secured Direct Lending - The secured direct lending fund intends to float on the Main Market on 15 December raising up to £100m